{"id":"monosialoganglioside-gm1","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL2303685","moleculeType":"Small molecule","molecularWeight":"739.77"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"GM1 is a naturally occurring glycosphingolipid found in neuronal cell membranes that acts as a ligand for growth factor receptors and facilitates cell-to-cell interactions. It enhances nerve growth factor (NGF) signaling and promotes axonal regeneration, making it useful in treating peripheral nerve injuries and neurodegenerative conditions. The drug works by stabilizing neuronal membranes and promoting the survival and differentiation of nerve cells.","oneSentence":"Monosialoganglioside GM1 is a ganglioside that promotes neuronal repair and regeneration by enhancing neurite outgrowth and protecting neurons from damage.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:55:44.291Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Peripheral nerve injury and regeneration"},{"name":"Acute ischemic stroke"},{"name":"Spinal cord injury"},{"name":"Diabetic neuropathy"}]},"trialDetails":[{"nctId":"NCT06742216","phase":"PHASE3","title":"Monosialoganglioside in Acute Ischemic Stroke: a Randomized, Blinded and Multicenter Confirmatory Study","status":"COMPLETED","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2020-11-03","conditions":"Acute Ischemic Stroke","enrollment":1232},{"nctId":"NCT04538833","phase":"PHASE2","title":"GM1 in the Treatment of Neurotoxicity Induced by Albumin-bound Paclitaxel","status":"WITHDRAWN","sponsor":"Henan Cancer Hospital","startDate":"2020-09-09","conditions":"Early Breast Cancer","enrollment":""},{"nctId":"NCT04952064","phase":"PHASE4","title":"An Exploratory Study of Ganglioside GM1 in Acute Ischemic Stroke","status":"COMPLETED","sponsor":"General Hospital of Shenyang Military Region","startDate":"2021-07-28","conditions":"Stroke, Ischemic","enrollment":300},{"nctId":"NCT01882621","phase":"PHASE3","title":"Monosialoganglioside(GM1) Preventing Neurotoxicity Induced by Cisplatin Contained Chemotherapy in NSCLC Patients","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2013-10","conditions":"Non-small Cell Lung Cancer","enrollment":300},{"nctId":"NCT02500810","phase":"PHASE2","title":"Monosialoganglioside Preventing Neurotoxicity Induced by Albumin-bound Paclitaxel Chemotherapy in Lung Cancer Patients","status":"UNKNOWN","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2015-07","conditions":"Neurotoxicity","enrollment":106}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":309,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["GM1"],"phase":"marketed","status":"active","brandName":"Monosialoganglioside GM1","genericName":"Monosialoganglioside GM1","companyName":"General Hospital of Shenyang Military Region","companyId":"general-hospital-of-shenyang-military-region","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Monosialoganglioside GM1 is a ganglioside that promotes neuronal repair and regeneration by enhancing neurite outgrowth and protecting neurons from damage. Used for Acute ischemic stroke, Peripheral nerve injury, Spinal cord injury.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}